These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 27531819)

  • 21. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Wimberly H; Brown JR; Schalper K; Haack H; Silver MR; Nixon C; Bossuyt V; Pusztai L; Lannin DR; Rimm DL
    Cancer Immunol Res; 2015 Apr; 3(4):326-32. PubMed ID: 25527356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor Microenvironment in Male Breast Carcinoma with Emphasis on Tumor Infiltrating Lymphocytes and PD-L1 Expression.
    Brcic I; Kluba AM; Godschachner TM; Suppan C; Regitnig P; Dandachi N; Lax SF; Balić M
    Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Markers associated with genomic instability, immunogenicity and immune therapy responsiveness in Metaplastic carcinoma of the breast: Expression of γH2AX, pRPA2, P53, PD-L1 and tumor infiltrating lymphocytes in 76 cases.
    Voutilainen S; Heikkilä P; Bartkova J; Nevanlinna H; Blomqvist C; Bartek J; Mattson J
    BMC Cancer; 2022 Dec; 22(1):1298. PubMed ID: 36503417
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations.
    Deb S; Wong SQ; Li J; Do H; Weiss J; Byrne D; Chakrabarti A; Bosma T; ; Fellowes A; Dobrovic A; Fox SB
    Br J Cancer; 2014 Dec; 111(12):2351-60. PubMed ID: 25490678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
    Zhou T; Xu D; Tang B; Ren Y; Han Y; Liang G; Wang J; Wang L
    Anticancer Drugs; 2018 Oct; 29(9):904-910. PubMed ID: 30085937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
    Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic value of stromal tumour infiltrating lymphocytes and programmed cell death-ligand 1 expression in breast cancer.
    Polónia A; Pinto R; Cameselle-Teijeiro JF; Schmitt FC; Paredes J
    J Clin Pathol; 2017 Oct; 70(10):860-867. PubMed ID: 28373294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of Targeted Therapy and Immuno-Oncology in Cancers Metastatic to the Breast.
    Vranic S; Senarathne W; Stafford P; Poorman K; Pockaj BA; Gatalica Z
    Appl Immunohistochem Mol Morphol; 2020 Oct; 28(9):661-668. PubMed ID: 31517642
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Whole-exome analysis of metaplastic breast carcinomas with extensive osseous differentiation.
    Beca F; Sebastiao APM; Pareja F; Dessources K; Lozada JR; Geyer F; Selenica P; Zeizafoun N; Wen HY; Norton L; Brogi E; Weigelt B; Reis-Filho JS
    Histopathology; 2020 Aug; 77(2):321-326. PubMed ID: 32043609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics.
    Anders CK; Abramson V; Tan T; Dent R
    Am Soc Clin Oncol Educ Book; 2016; 35():34-42. PubMed ID: 27249684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.
    Garber ST; Hashimoto Y; Weathers SP; Xiu J; Gatalica Z; Verhaak RG; Zhou S; Fuller GN; Khasraw M; de Groot J; Reddy SK; Spetzler D; Heimberger AB
    Neuro Oncol; 2016 Oct; 18(10):1357-66. PubMed ID: 27370400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular analyses of triple-negative breast cancer in the young and elderly.
    Aine M; Boyaci C; Hartman J; Häkkinen J; Mitra S; Campos AB; Nimeus E; Ehinger A; Vallon-Christersson J; Borg Å; Staaf J
    Breast Cancer Res; 2021 Feb; 23(1):20. PubMed ID: 33568222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 expression in small cell neuroendocrine carcinomas.
    Schultheis AM; Scheel AH; Ozretić L; George J; Thomas RK; Hagemann T; Zander T; Wolf J; Buettner R
    Eur J Cancer; 2015 Feb; 51(3):421-6. PubMed ID: 25582496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.